1. Preventing epidemics through science
A global strategy for epidemic preparedness
Blueprint for research and development

2. Research Response in West Africa
Ebola: R&D response
Funds .
1st Vx P1 trial
Research Response in West Africa
1st Drug trial 1st CP use
1st Dx-PCR
Next time…
1st Vx trial
P3 Ring Vx
1st Dx-RDT

3. 68th World Health Assembly, 2015
“….welcomed the development of a Blueprint — in consultation with Member States and relevant stakeholders— for accelerating research and
development in epidemics where there are no, or insufficient, preventive, and curative solutions, taking
into account other relevant work-streams within WHO”

4. G7 Health Ministers, G7 2015
“…continued financing, collaboration and coordination ….through initiatives such as WHO blueprint for R&D preparedness and the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R).”

5. Blueprint tasks
Develop (and implement) a roadmap for R&D preparedness for known priority pathogens, and
Enable roll-out of an emergency R&D response as early and as efficiently as possible

6. Blueprint role: to expedite
Co-ordinate the players
Promote cross-discipline collaboration
Confront obstacles, e.g. legal and ethical issues
Expedite funding quests
Encourage innovation
Maintain flexibility

7. Blueprint focus Highly infectious pathogens
Their potential for global public-health emergencies
All R&D aspects

8. Development of the Blueprint
Building on the efforts of others
A collaborative effort with Member States and other relevant stakeholders
Consultations
Scientific Advisory Group
Several consultations have been held and a series of other are scheduled to address key questions

9. Expected benefits
Better R&D preparedness for diseases that might lead to epidemics
Portfolio of promising experimental medical technologies with results available from Phase 1 safety trials in man
Better readiness to promptly conduct R&D during an emergency
Mechanisms to improve global coordination

10. Five work-streams WS1 WS5 WS2 WS3 WS4 Disease priorities
Stakeholder coordination
WS1
Disease priorities
WS2
Research priorities
WS4
Assessment
WS5
Innovative funding options

11. Initial Blueprint deliverables

12. Initial Blueprint deliverables
Meeting of experts to prioritize pathogens
WS1
Public consultation on MERS-CoV roadmap
Production Platform technologies
Zika R&D
WS2
Database or resources
Templates & global norms
Toolbox for CT design
WS3
Performance monitoring mechanism
WS4
Consultation for funding options
WS5
CCHF, Filoviruses, Lassa, Severe Coronaviruses, Nipah, RVF. Considered as “serious”: Chikungunya, SFTS, and Zika, December 2015

13. Initial Blueprint deliverables
Meeting of experts to prioritize pathogens
WS1
Public consultation on MERS-CoV roadmap
Production Platform technologies
Zika R&D
WS2
Database or resources
Templates & global norms
Toolbox for CT design
WS3
Performance monitoring mechanism
WS4
Consultation for funding options
WS5
- Final MERS-CoV roadmap April 2016
- Platform: review of proposals for, 4-7 April 2016

14. Initial Blueprint deliverables
Meeting of experts to prioritize pathogens
WS1
Public consultation on MERS-CoV roadmap
Production Platform technologies
Zika R&D
WS2
Database of resources
Toolbox
Template &global norms
WS3
Performance monitoring mechanism
WS4
Consultation for funding options
WS5
- Mapping of activities: concept note, April 2016
- Meeting on toolbox for Ph 3 Vaccine trial, March
- MTA drafted, Data sharing: ICJME recommendations

15. ICJME Recommendations, 2015
Data Sharing
ICJME Recommendations, 2015

16. Initial Blueprint deliverables
Meeting of experts to prioritize pathogens
WS1
Public consultation on MERS-CoV roadmap
Production Platform technologies
Zika R&D
WS2
Database or resources
Templates & global norms
Toolbox for CT design
WS3
Performance monitoring mechanism
WS4
Consultation for funding options
WS5
Monitoring & Evaluation framework, April 2016

17. Initial Blueprint deliverables
Meeting of experts to prioritize pathogens
WS1
Public consultation on MERS-CoV roadmap
Production Platform technologies
Zika R&D
WS2
Database or resources
Templates & global norms
Toolbox for CT design
WS3
Meeting for performance monitoring mechanism
WS4
Consultation for funding options
WS5
Potential finding mechanisms, April 2016

18. Key Milestone January 2016: report to the Executive Board
May 2016: Blueprint presented at the WHA for consideration by member states

19. R&D response to Zika
1 Feb: PHEIC declared for microcephaly and neurological disorders
4 Feb: 1st R&D Blueprint meeting on Zika
Feb - March:
. 7-9 March: Global consultation to discuss joint planning for accelerated product development and evaluation
Zika product pipeline
TPP for Diagnostic & Vaccine
Product developers to submit their products to the WHO EUAL procedure by 31 March 2016

20. WHO meetings on Zika
14–15 March. Vector Control Advisory Group meeting, Geneva
17–19 March. Management of complications/clinical manifestation of Zika virus disease, Geneva
17–18 March. Harmonization of study protocols, Recife

21. WHO Blueprint secretariat
Lead: Marie-Paule Kieny
WS-1: Cathy Roth
WS2: David Wood & Vasee Moorthy
WS3: Ana Maria Henao Restrepo
WS4: Claudia Nannei
WS5: Peter Beyer